All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F18%3A00069034" target="_blank" >RIV/65269705:_____/18:00069034 - isvavai.cz</a>

  • Alternative codes found

    RIV/60162694:G44__/18:43889628 RIV/00216224:14110/18:00101862 RIV/00216208:11110/18:10382061 RIV/00216208:11150/18:10382061 and 2 more

  • Result on the web

    <a href="https://www.sciencedirect.com/science/article/pii/S2152265018305615" target="_blank" >https://www.sciencedirect.com/science/article/pii/S2152265018305615</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.clml.2018.06.030" target="_blank" >10.1016/j.clml.2018.06.030</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia

  • Original language description

    We evaluated the usefulness of flow cytometry (FCM) and real-time quantitative polymerase chain reaction (PCR) in the assessment of minimal residual disease (MRD) in adult acute lymphoblastic leukemia. The analysis showed that both FCM and real-time quantitative PCR MRD methods are sensitive for survival prediction during induction. However, FCM was not sufficiently sensitive in later phases of treatment. Background: Minimal residual disease (MRD) is an important prognostic maker in acute lymphoblastic leukemia (ALL). However, few data comparing the measurement of adult ALL MRD using different methods in daily practice are available. We conducted an analysis comparing the importance of flow cytometry (FCM) and real-time quantitative polymerase chain reaction (PCR) in the assessment of MRD in adult ALL. Patients and Methods: Fifty-six consecutive adult patients with both Philadelphia-negative and -positive ALL treated according to an intensive protocol were enrolled in the study. Bone marrow samples were acquired on day 26 and during week 11 of treatment. MRD evaluation was performed using 8-color FCM and PCR of immunoglobulin or T-cell receptor gene clonal rearrangements and BCR-ABL1, KMT2A-AF4 and E2A-PBX1 fusion genes. Results: On day 26, both FCM and PCR seemed to have good discrimination sensitivity for overall survival (P =.001 to.008) and progression-free survival (P =.03 to.04) prediction for both Philadelphia-positive and -negative cases. The most sensitive method in week 11 was PCR including all results &gt; 0 considered to indicate MRD positivity (P =.002 for overall survival and P =.02 for progression-free survival). PCR with other cutoffs was not sufficiently sensitive in week 11. Moreover, no FCM thorn samples were found in week 11. The subanalysis of the Philadelphia-negative patients showed similar results. Conclusion: Our analysis showed that both FCM and PCR MRD assessment methods are sensitive for survival prediction during induction. However, we believe FCM could not be sufficiently sensitive in later phases of treatment. (C) 2018 Elsevier Inc. All rights reserved.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Clinical Lymphoma Myeloma &amp; Leukemia

  • ISSN

    2152-2650

  • e-ISSN

  • Volume of the periodical

    18

  • Issue of the periodical within the volume

    11

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    6

  • Pages from-to

    743-748

  • UT code for WoS article

    000448263400013

  • EID of the result in the Scopus database

    2-s2.0-85050389697